Literature DB >> 7685514

Susceptibility and resistance to J3V1 retrovirus-induced murine plasmacytomagenesis in reconstituted severe combined immunodeficient mice.

D M Hilbert1, J G Pumphrey, J Troppmair, U R Rapp, S Rudikoff.   

Abstract

To date much is known about the genetics of susceptibility and resistance to plasmacytoma induction in mice, however little is known about the cellular aspects of these phenotypes. The complexity of plasmacytomagenesis allows for susceptibility and resistance to reflect differences in B cells, T cells, accessory cells and/or stromal elements contributing to the disease process. Alternatively, these phenotypes may result from differential abilities to affect events critical to plasmacytomagenesis, such as myc deregulation. To address these possibilities, the v-myc-raf-containing retrovirus, J3V1, was used to induce plasmacytomas (PCTs) in severe combined immunodeficient (SCID) mice reconstituted with susceptible (Balb/c) and/or resistant (DBA/2) cells. The results demonstrate that Balb/c bone marrow (BM)-reconstituted SCID mice yielded PCTs of donor origin, while DBA/2 BM-reconstituted mice did not. Mice reconstituted with both DBA/2 BM and Balb/c peripheral lymphocytes, as well as those reconstituted with Balb/c peripheral lymphocytes alone, also yielded only Balb/c PCTs. These results indicate that: (1) a microenvironment supportive of plasmacytomagenesis is insufficient to allow PCT development among resistant cells; (2) DBA/2 BM-derived cells do not suppress plasmacytomagenesis by target cell elimination or microenvironment destruction; (3) resistance is not solely attributable to the inability of DBA/2 B cells to deregulate myc; and (4) potential PCT targets reside in a number of lymphoid tissues. Taken together, these results demonstrate that a major aspect of resistance/susceptibility to plasmacytomagenesis is dictated by the genotype of the target B cell.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685514

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia.

Authors:  N Swaminathan; G Lopez-Berestein; S Rudikoff
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Authors:  D M Hilbert; M Y Shen; U R Rapp; S Rudikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

3.  Interleukin 6 is essential for in vivo development of B lineage neoplasms.

Authors:  D M Hilbert; M Kopf; B A Mock; G Köhler; S Rudikoff
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.